

TECHNOLOGY OFFER

PHOSPHOLIPIDS FOR TREATMENT OF INFLAMMATION AND LUNG EDEMA

Sepsis induced by Gram-positive or/and Gram-negative bacteria is a leading cause of death in developed countries and the most common cause of death among critically ill patients. Respiratory tract is the most common site of infections that are associated with the highest mortality. The acute respiratory distress syndrome, which is characterized by a combination of lung edema and acute inflammation, continues to be a major health care problem. University of Graz and University of Chicago offer unique lead compounds simultaneously targeting sepsis as well as lung edema due to their unique pharmacological mode of action.

BACKGROUND


The incidence of severe sepsis in the United States, is estimated to be 300 cases per 100 000 population (> 0.5 million cases per year), with at least a third being lethal. Acute respiratory distress syndrome is affecting more than 190 000 people in the US annually with a mortality of up to 45% depending on the severity of the illness and co-morbidities.

TECHNOLOGY

The technology describes chemically modified phospholipase-resistant phospholipids that demonstrate simultaneously two types of activities. First, these compounds inhibit activation of Toll-like receptors 4 and 2 by components of Gram-positive and Gram-negative bacteria and demonstrate protection from lethal sepsis in animal models. Second, these compounds enhance endothelial barrier in lung vessels, reverse the action of mediators causing edema and prevent formation of lung edema in vivo. This polypharmacological mode of action can make these compounds especially effective for treatment of severe infections often leading to the development of lung edema.

ADVANTAGES

- New polypharmacological mode of action: the same molecules act as TLR antagonists and protectors of endothelial barrier
- unique double-specific Toll-like receptor TLR4 and TLR2 antagonists: may be especially effective in prevention and treatment of lung edema induced by polybacterial sepsis
- lung endothelial barrier-protection stronger and more sustainable than by all currently known barrier protectors
- increased biostability of phospholipid structure due to phospholipase-resistant bonds
- The chemical structure allows simple linking of variable small molecules and drugs to the phospholipid scaffold thus increasing their half-life and pharmacological effect



© Bochkov/Oskolkova

KEYWORDS:

TOLL-LIKE RECEPTOR
ANTAGONISTS
LUNG ENDOTHELIAL BARRIER
PROTECTION
SEPSIS
LUNG EDEMA

INVENTORS:

BOCHKOV, VALERY
BIRUKOV, KONSTANTIN
BIRUKOVA, ANNA
OSKOLKOVA, OLGA

COOPERATION OPTIONS:

LICENSING AGREEMENT
RESEARCH COOPERATION
AGREEMENT

DEVELOPMENT STATUS:

PRE-CLINICAL COMPOUNDS

STATUS OF PATENTS:

EUROPEAN PATENT FILED
(PCT/EP2018/070481)
US PATENT FILED
(PCT/EP2018/070481)
CANADIAN PATENT FILED
(PCT/EP2018/070481)

REFERENCE NUMBER

2016_11

CONTACT:

Gernot Faustmann

University of Graz
Research Management/Service
Universitätsplatz 3
8010 Graz / Austria
T: +43 316 380 3994
gernot.faustmann@uni-graz.at
www.uni-graz.at